头孢哌酮联合舒巴坦治疗肾盂肾炎的临床疗效和生存质量研究

目的 研究头孢哌酮联合舒巴坦治疗肾盂肾炎的有效性、安全性以及评价两方案的生存质量。方法 按纳入标准选取海口市人民医院收治的100例肾盂肾炎患者，随机分成治疗组和对照组，每组各50例患者，治疗组采用头孢哌酮联合舒巴坦治疗，对照组采用左氧氟沙星治疗，观察两组临床疗效及复发率，并观察不良反应情况；同时，采用生存质量综合评定问卷（GQOLI-74）对患者生存质量进行评定。结果 在临床疗效方面，治疗组总有效率为90%，无复发；对照组总有效率为56%，复发2例，复发率为4%。在安全性方面，治疗组的不良反应发生率为18%，对照组的不良反应发生率为20%，不良反应率的差异无统计学意义。在生存质量方面，治疗组与对照组在认知功能、婚姻与家庭、住房、社区服务和生活环境等5个测量因子数值无统计学意义差异，其他测量因子数值具有统计学差异（P<0.05），生存质量总体评价治疗组优于对照组（P<0.05）。结论 相比于左氧氟沙星，头孢哌酮联合舒巴坦治疗肾盂肾炎疗效更好，建议将头孢哌酮联合舒巴坦治疗肾盂肾炎作为优先考虑的治疗方案。

To study the clinical effectiveness and quality of survival of levofloxacin and cefoperazone sulbactam in patients with pyelonephritis

Objective To study the effectiveness, safety and quality of survival of cefoperazone sodium combined with sulbactam in the treatment of pyelonephritis. Methods According to the inclusion criteria, 100 cases of patients with pyelonephritis were selected and randomly divided into the treatment group and control group with no statistical difference. Each group had 50 cases. The treatment group was treated with cefoperazone combined sulbactam, control group was treated with levofloxacin. The clinical curative effect and the recurrence rate of the two groups were observed, and the adverse reaction conditions were observed too. At the same time, the quality of life of patients was evaluated by using the comprehensive evaluation questionnaire (GQOLI-74). Results In terms of clinical effectiveness, the total effective rate of treatment group was 90%, with no recurrence; the total effective rate of control group was 56%, and the recurrence rate was 4%. In terms of clinical safety, the incidence of adverse reactions was 18% in treatment group, the incidence of adverse reactions was 20% in the control group. There was no statistically significant difference in the rate of adverse reactions. In terms of quality of survival, five measuring factors including cognitive function, marriage and family, housing, community services and living environment of the treatment group and control group had no statistically significant difference, and other measurement factors had statistically difference (P<0.05). Overall evaluation of the quality of life was better than that of the control group (P<0.05). Conclusion Compared with levofloxacin, cefoperazone combined with sulbactam has better clinical effectiveness in the patients with pyelonephritis. Cefoperazone sulbactam is suggested as the preferred treatment.